文献速递心脑血管急症重症综合管理与镇静镇痛

冠状动脉内输注间充质干细胞预防急性心肌梗死后心力衰竭:3期随机临床试验(PREVENT-TAHA8)

Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).
PubMed 文献 · BMJ · 2025-10-29
一句话结论首次ST段抬高型急性心肌梗死且左室射血分数<40%的患者,在发病3–7天内冠状动脉内输注同种异体沃顿胶来源间充质干细胞,可降低心力衰竭发生率(HR 0.43)。

这项在伊朗设拉子3家三级医院开展的3期随机临床试验纳入420例首次ST段抬高型急性心肌梗死且左室射血分数<40%的患者,按1:2随机接受冠状动脉内输注同种异体沃顿胶来源间充质干细胞联合标准治疗或单纯标准治疗,中位随访33.2个月。最终分析396例(干预组136例、对照组260例)。干预组心力衰竭发生率2.77 vs 6.48/100人年(HR 0.43,95%CI 0.21–0.89,P=0.024)、因心力衰竭再住院0.92 vs 4.20/100人年(HR 0.22,95%CI 0.06–0.74,P=0.015)、心血管死亡与因心肌梗死或心力衰竭再住院的复合终点2.80 vs 7.16/100人年(HR 0.39,95%CI 0.19–0.82,P=0.012)均降低;因心肌梗死再住院、全因死亡、心血管死亡无显著差异;6个月时左室射血分数较基线的改善干预组更大(β=5.88,95%CI 4.00–7.76,P<0.001)。作者认为该技术可能作为心肌梗死后预防心力衰竭、降低未来不良事件的辅助手段。

要点

  • 首次ST段抬高型心肌梗死且左室射血分数<40%者,发病3–7天内冠状动脉内输注同种异体沃顿胶来源间充质干细胞,心衰发生率2.77 vs 6.48/100人年(HR 0.43,95%CI 0.21–0.89)。
  • 因心衰再住院0.92 vs 4.20/100人年(HR 0.22,95%CI 0.06–0.74,P=0.015),干预组更低。
  • 心血管死亡与因心肌梗死或心衰再住院的复合终点2.80 vs 7.16/100人年(HR 0.39,95%CI 0.19–0.82,P=0.012)。
  • 全因死亡(HR 1.10,95%CI 0.40–3.02,P=0.86)、心血管死亡(HR 0.68,95%CI 0.18–2.57,P=0.57)、因心肌梗死再住院(HR 0.40,95%CI 0.14–1.19,P=0.10)均无显著差异。
  • 6个月左室射血分数较基线改善干预组更大(β=5.88,95%CI 4.00–7.76,P<0.001)。

适用人群与场景

  • 首次ST段抬高型急性心肌梗死且左室射血分数<40%的患者。
  • 在伊朗设拉子3家三级医院入组,共420例随机、396例纳入最终分析(干预组136例、对照组260例)。

处置流程与药物剂量

  • 在急性心肌梗死发病3–7天内,于标准治疗基础上冠状动脉内输注同种异体沃顿胶来源间充质干细胞。
  • 对照组仅接受标准治疗。

研究设计与关键结果

  • 3期随机临床试验,伊朗设拉子3家三级医院,420例首次ST段抬高型急性心肌梗死且左室射血分数<40%的患者按1:2随机分为干预组与标准治疗组,396例纳入最终分析,中位随访33.2个月。
  • 主要终点心衰发生率:干预组2.77 vs 对照组6.48/100人年(HR 0.43,95%CI 0.21–0.89,P=0.024)。
  • 因心衰再住院:干预组0.92 vs 对照组4.20/100人年(HR 0.22,95%CI 0.06–0.74,P=0.015)。
  • 心血管死亡与因心肌梗死或心衰再住院的复合终点:干预组2.80 vs 对照组7.16/100人年(HR 0.39,95%CI 0.19–0.82,P=0.012)。
  • 因心肌梗死再住院:干预组1.23 vs 对照组3.06/100人年(HR 0.40,95%CI 0.14–1.19,P=0.10),无显著差异。
  • 全因死亡:干预组1.81 vs 对照组1.66/100人年(HR 1.10,95%CI 0.40–3.02,P=0.86),无显著差异。
  • 心血管死亡:干预组0.91 vs 对照组1.33/100人年(HR 0.68,95%CI 0.18–2.57,P=0.57),无显著差异。
  • 6个月左室射血分数较基线改善:干预组大于对照组(β=5.88,95%CI 4.00–7.76,P<0.001)。

证据类型、等级与局限

  • 证据类型:3期随机临床试验。
  • 作者结论:该技术可能作为心肌梗死后预防心力衰竭、降低未来不良事件的辅助手段。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对首次ST段抬高型急性心肌梗死且左室射血分数<40%的患者,作者认为在发病3–7天内冠状动脉内输注同种异体沃顿胶来源间充质干细胞可能作为心肌梗死后的辅助手段,以预防心力衰竭发生、降低未来不良事件风险。
  • 该干预在因心衰再住院和心血管死亡与因心肌梗死或心衰再住院的复合终点上显示降低,但对全因死亡、心血管死亡、因心肌梗死再住院未见显著影响。

指南或共识出处

  • PREVENT-TAHA8,ClinicalTrials.gov NCT05043610

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure.

DESIGN: Phase 3 randomised clinical trial.

SETTING: Three tertiary hospitals in Shiraz, Iran.

PARTICIPANTS: 420 patients with a first ST segment elevation acute myocardial infarction and left ventricular ejection fraction <40% were enrolled and randomised in a 1:2 ratio to receive intervention or standard care.

INTERVENTION: Intracoronary infusion of allogenic Wharton's jelly derived mesenchymal stem cells within 3-7 days of acute myocardial infarction in addition to standard care.

MAIN OUTCOME MEASURES: The primary endpoint was incidence of heart failure. Secondary endpoints included readmission to hospital for heart failure, all cause mortality, cardiovascular mortality, and readmission to hospital for myocardial infarction. Changes in left ventricular ejection fraction within six months post-myocardial infarction were compared between groups.

RESULTS: A total of 396 patients (136 in the intervention group and 260 in the control group) were included in the final analysis, with a median follow-up of 33.2 months. Intracoronary infusion of mesenchymal stem cells had a preventive effect for incidence of heart failure (2.77 v 6.48 per 100 person years; hazard ratio 0.43, 95% confidence interval 0.21 to 0.89; P=0.024), readmission to hospital for heart failure (0.92 v 4.20 per 100 person years; 0.22, 0.06 to 0.74; P=0.015), and a composite endpoint of cardiovascular mortality and readmission for myocardial infarction or heart failure (2.80 v 7.16 per 100 person years; 0.39, 0.19 to 0.82; P=0.012). The intervention did not have a statistically significant effect on readmission to hospital for myocardial infarction (1.23 v 3.06 per 100 person years; hazard ratio 0.40, 0.14 to 1.19; P=0.10), all cause mortality (1.81 v 1.66 per 100 person years; 1.10, 0.40 to 3.02; P=0.86), or cardiovascular mortality (0.91 v 1.33 per 100 person years; 0.68, 0.18 to 2.57; P=0.57). Left ventricular ejection fraction in the intervention group showed a significantly greater improvement from baseline at six months compared with the control group (β=5.88, 95% confidence interval 4.00 to 7.76; P<0.001).

CONCLUSIONS: Intracoronary infusion of Wharton's jelly derived mesenchymal stem cells significantly reduced the risk of incidence of heart failure, readmission to hospital for heart failure, and the composite endpoint of cardiovascular mortality and readmission to hospital for heart failure or myocardial infarction in patients after an acute myocardial infarction, suggesting that this technique may serve as a valuable adjunctive procedure after myocardial infarction to prevent the development of heart failure and reduce the risk of future adverse events.

TRIAL REGISTRATION: ClinicalTrials.gov NCT05043610.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Attar A, Mirhosseini SA, Mathur A, et al. Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). BMJ. 2025. PMID: 41224473. doi:10.1136/bmj-2024-083382

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。